Testosterone Replacement Therapy

There is a particular kind of tiredness that doesn't go away after a good night's sleep — a muted quality to the day, a fading interest in things that used to matter, a body that no longer responds the way it once did. For many men, and more women than most people realize, that experience has a hormonal dimension.

Testosterone replacement therapy is the clinical restoration of testosterone to physiologic levels in people whose bodies are no longer producing enough on their own. It doesn't override the body's intelligence — it restores the biological conditions under which that intelligence operates best. When indicated and properly managed, TRT can meaningfully shift energy, mood, body composition, bone health, and sexual vitality in ways that reach across daily life.

At RegenLife, clinicians approach hormone therapy as part of a broader framework of metabolic and lifestyle health — not a standalone fix, but a carefully evaluated intervention that works best when it's grounded in thorough diagnostics, honest goal-setting, and ongoing monitoring. This guide covers the science, the delivery methods, the evidence, and everything patients need to understand before starting.

Key Takeaways

• Testosterone deficiency (hypogonadism) affects an estimated 4–5 million men in the U.S. and is widely underdiagnosed; women are also significantly affected, particularly around perimenopause
• The landmark TRAVERSE trial (2023, 5,246 men) published in the New England Journal of Medicine found TRT was non-inferior to placebo for major cardiovascular events — resolving nearly a decade of safety uncertainty
• TRT's strongest evidence is for sexual function, bone density, body composition, and mood in people with confirmed low testosterone; results for energy and cognition are more variable
• Effective TRT requires regular monitoring — testosterone levels, blood count, PSA, and estradiol — to maintain safety and optimize outcomes

Understanding Testosterone and Why It Declines

The Natural Arc of Testosterone

Testosterone is a steroid hormone produced primarily in the testes in men and in the ovaries and adrenal glands in women. It governs far more than sexual function — it shapes muscle development, bone density, red blood cell production, fat distribution, mood regulation, and cognitive drive. In men, levels peak in the late teens to mid-20s, then decline at a rate of roughly 1–2% per year beginning around age 30 to 35.

That slow decline is a normal part of aging for most men. But for some, the decline reaches a threshold — below 300 ng/dL on fasting morning measurements, combined with consistent symptoms — that crosses into clinical hypogonadism. Over 60% of men over 65 have free testosterone levels below the normal range for men aged 30 to 35. And it's not only an aging story: hypogonadism is most commonly diagnosed in men aged 35 to 44, driven by factors including chronic stress, metabolic dysfunction, sleep deprivation, opioid use, and pituitary issues.

The American Urological Association guideline requires two separate fasting morning testosterone measurements below 300 ng/dL, plus at least one consistent symptom, before a diagnosis of testosterone deficiency is made. This standard is important — testosterone fluctuates, and a single measurement isn't sufficient to guide treatment decisions.

Recognizing the Symptoms of Low Testosterone in Men

The experience of low testosterone is often gradual and easy to attribute to stress, aging, or just "being busy." The symptoms are real but non-specific — which is partly why the condition is so often missed.

Beyond these classic presentations, the AUA guideline recommends testosterone testing in men with unexplained anemia, bone density loss, diabetes, HIV/AIDS, chronic opioid use, or prior chemotherapy — even in the absence of classic symptoms.

Testosterone and Women: An Overlooked Connection

Testosterone is not a male-only hormone. Women produce testosterone in the ovaries and adrenal glands at levels roughly 10 to 20 times lower than men — but physiologically meaningful. Female testosterone peaks in the mid-20s and declines steadily, with a significant drop during perimenopause and postmenopause.

Low testosterone in women presents differently than in men: the most documented symptom is reduced sexual desire (classified clinically as Hypoactive Sexual Desire Disorder, or HSDD), alongside fatigue, mood changes, muscle mass reduction, and cognitive symptoms. A 2024 study of 510 peri- and postmenopausal women using transdermal testosterone found 52% reported libido improvement, 47% mood improvement, and 39% cognitive improvement at 12 weeks.

Diagnosis in women is more nuanced because laboratory reference ranges are less standardized than in men, and symptoms overlap with thyroid conditions, depression, and iron deficiency anemia. RegenLife's diagnostic services evaluate the full hormonal picture — thyroid, adrenal, estrogen, progesterone, and testosterone — to distinguish the root drivers of symptoms rather than treating any single number in isolation.

How TRT Is Administered: Choosing the Right Method

There is no universally superior delivery method. The best approach depends on a patient's lifestyle, preference for adherence routine, tolerance for injection, and clinical response. Satisfaction rates across methods are broadly comparable — roughly 68–73% — which means patient preference should guide the decision.

Injections

Testosterone cypionate or enanthate, administered intramuscularly or subcutaneously, is the most cost-effective and widely used method. Injections are typically given weekly or every two weeks.

The advantage is precise dose control and strong pharmacokinetic data. The limitation is a "peak and trough" pattern — testosterone spikes two to five days after injection, then returns toward baseline before the next dose. Some patients notice this fluctuation as variable energy or mood. Weekly injections reduce this swing compared to biweekly schedules.

Testosterone undecanoate (clinic-administered every 10 to 14 weeks) is an option for patients who prefer infrequent dosing and can attend clinic visits.

Gels, Creams, and Patches

Daily transdermal testosterone — applied to the shoulders, upper arms, or abdomen — produces more stable testosterone levels than injections, avoiding the peak-trough effect. It's non-invasive and allows straightforward dose adjustment. The primary limitation is the requirement for daily application and the risk of transferring testosterone to partners or children via skin contact.

Patches offer a similar steady-state absorption profile with the added advantage of a once-daily application, though skin irritation is the most common complaint.

Pellets

Subcutaneous pellets are implanted every three to six months in a brief in-office procedure, typically in the hip or buttock area. They release testosterone steadily over time, producing the most physiologically consistent hormone levels of any delivery method.

The practical appeal is significant: no daily routine, no weekly injections. RegenLife's hormone therapy program includes pellet implantation for patients who are good candidates. The limitation is reduced flexibility — once implanted, the dose cannot be adjusted until the pellets dissolve. If a side effect emerges, it cannot be immediately reversed.

A comparison of delivery methods shows that all three major approaches (injections, gels, pellets) reliably restore testosterone to mid-normal range. The clinical choice is ultimately about matching the method to the patient's life.

What TRT Actually Does: Evidence from the Research

Sexual Function and Libido

This is TRT's most consistently demonstrated benefit across the research literature. Improvements in sexual desire, arousal, and erectile function typically emerge within three to eight weeks of initiation, with stabilization around six months. The effect is strongest when the underlying problem is confirmed low testosterone — TRT is not a treatment for erectile dysfunction that originates from vascular or psychogenic causes.

The Testosterone Trials (TTrials) — a landmark NIH-funded set of seven coordinated randomized controlled trials in 788 older men — found that the Sexual Function trial showed significantly improved sexual activity (effect size 0.45), with 20% of TRT participants reporting being "much better" compared to fewer than 10% in the placebo group. This is the kind of effect that translates into real daily life.

For women with HSDD, testosterone therapy endorsed by the International Society for the Study of Women's Sexual Health (ISSWSH) shows consistent improvements in satisfying sexual events and sexual distress scores across multiple randomized trials.

Body Composition and Physical Strength

Testosterone is a primary driver of muscle protein synthesis and fat mobilization. TRT's effects on body composition are measurable by two to three months and continue building for a year or more. Meta-analytic data consistently show increased lean muscle mass and reduced fat mass — particularly visceral abdominal fat, which independently raises cardiovascular and metabolic risk.

This is not a passive effect. At RegenLife, clinicians notice that patients who combine TRT with structured exercise therapy and nutritional support see meaningfully better body composition outcomes than those who treat TRT as a standalone intervention. The hormone restores the biological conditions; the training and nutrition direct where that capacity goes.

For patients working through weight management goals, optimizing testosterone levels can remove a hormonal headwind that makes fat loss and muscle retention disproportionately difficult despite consistent effort.

Bone Density and Blood Health

One of TRT's most robust and often underappreciated benefits is its effect on bone. The TTrials Bone sub-trial (211 participants) documented a 6.8% increase in trabecular volumetric bone mineral density in the spine and an 8.5% increase in estimated bone strength — both statistically significant at p≤0.001. For patients whose bone density has quietly eroded through years of low testosterone, this is a meaningful structural protection against fracture risk.

TRT also supports red blood cell production. In the TTrials Anemia sub-trial (126 men), 54% of the testosterone group versus 15% of placebo achieved a hemoglobin increase of at least 1.0 g/dL — a clinically meaningful result for men with unexplained anemia that hadn't responded to standard evaluation.

This is one of the reasons bone density monitoring, via DEXA scanning, and complete blood counts are part of RegenLife's ongoing diagnostic monitoring protocol.

Mood, Depression, and Mental Clarity

Testosterone influences dopamine and serotonin activity in the brain — two neurotransmitters central to motivation, emotional regulation, and mood stability. Low T is an independent risk factor for depression and anxiety in men, not simply a correlate.

A meta-analysis of 27 randomized controlled trials covering 1,890 men published in JAMA Psychiatry found that testosterone treatment was associated with a significant reduction in depressive symptoms compared to placebo (Hedges g = 0.21; OR = 2.30). The effect was stronger at higher doses and in men with greater baseline symptom variability.

At RegenLife, the behavioral health dimension of hormone therapy matters. Patients who are managing mild to moderate depression alongside confirmed low testosterone often find that addressing both — the hormonal substrate and the psychological patterns — produces outcomes that neither intervention alone could achieve. TRT is not a replacement for mental health care, but it may restore the biochemical foundation that makes that care more effective.

Cognitive effects are more modest. The TTrials found no significant improvement in formal measures of memory, spatial ability, or executive function in older men. Some secondary analyses suggest benefits for processing speed and spatial memory in younger patients, and research is ongoing.

Cardiovascular Safety: How a Decade of Uncertainty Was Finally Resolved

The Controversy That Shaped a Generation of Practice

In 2010, a VA study raised concerns about cardiovascular events in older hypogonadal men using testosterone. In 2013, an observational study echoed those concerns. The FDA responded in 2015 by mandating a large safety trial and adding cardiovascular warnings to all testosterone products. For nearly a decade, many physicians became hesitant to prescribe TRT — and many patients with genuine hormone deficiency went undertreated.

What the TRAVERSE Trial Established

The TRAVERSE trial — published in the New England Journal of Medicine in June 2023 — was a rigorous, double-blind, placebo-controlled non-inferiority study involving 5,246 men aged 45 to 80 with confirmed hypogonadism and either pre-existing cardiovascular disease or high cardiovascular risk.

The primary outcome — major adverse cardiovascular events (MACE: heart attack, stroke, cardiovascular death) — occurred in 7.0% of the testosterone group versus 7.3% of the placebo group. TRT was non-inferior to placebo. No increased risk of myocardial infarction or stroke.

The Cleveland Clinic's review of TRAVERSE noted two secondary signals worth monitoring: nonfatal arrhythmias requiring intervention (5.2% vs. 3.3%) and acute kidney injury (2.3% vs. 1.5%). These findings are relevant for men with pre-existing atrial fibrillation risk or kidney vulnerability, and they inform ongoing monitoring in RegenLife's clinical protocols.

The European Expert Panel position statement (2026) and Androgen Society guidelines both now affirm that TRT does not increase the risk of major cardiovascular events in men with confirmed hypogonadism when used as clinically indicated. The era of unnecessary hesitancy has passed.

Monitoring: What Ongoing Safety Looks Like

What Gets Measured and When

TRT is not a "prescribe and forget" therapy. Structured monitoring is built into safe clinical practice at every stage.

Before starting:

• Two fasting morning testosterone measurements (confirming <300 ng/dL)
• LH and FSH to classify hypogonadism type
• Complete blood count (hemoglobin and hematocrit)
• PSA in men aged 40 and over
• Estradiol if gynecomastia or breast symptoms are present
• Prolactin if pituitary pathology is suspected

During treatment:

Key thresholds to act on: Hematocrit above 54% requires dose reduction or temporary discontinuation. PSA rising more than 1.4 ng/mL above baseline within any 12-month period, or exceeding 4.0 ng/mL absolute, warrants urologic referral. Elevated estradiol with symptoms (gynecomastia, fluid retention, mood changes) may indicate need for dose adjustment or aromatase inhibitor.

Who Should Not Use TRT

Not everyone who wants TRT is a good candidate. Absolute contraindications include:

• Active or recently treated prostate cancer — testosterone fuels androgen-sensitive tumors; this is a firm contraindication in active disease
• Male breast cancer — also androgen-sensitive
• Untreated polycythemia (hematocrit >54%) — raises thrombosis risk
• Unreviewed PSA >4.0 ng/mL — urologic evaluation must precede initiation

Relative contraindications requiring careful clinical evaluation:

• Desire for future biological children — TRT suppresses sperm production by inhibiting the HPG axis; men hoping to father children should consider alternatives (clomiphene, FSH/hCG protocols) rather than exogenous testosterone
• Untreated obstructive sleep apnea — testosterone can worsen OSA
• Severe lower urinary tract symptoms or untreated BPH — may exacerbate symptoms
• Uncontrolled congestive heart failure — fluid retention risk

The 2025 GRIIP consensus on contraindications provides the most current formal framework for evaluating patients with oncological, infectious, or hematological comorbidities. At RegenLife, every TRT candidate undergoes thorough evaluation — not to create barriers, but to ensure that treatment is safe and the timing is right.

Supporting Testosterone Naturally: The Foundation That Makes Everything Work Better

Whether or not TRT is part of someone's plan, the lifestyle factors that influence testosterone are worth understanding. For patients in the borderline range, lifestyle optimization alone may be sufficient. For patients on TRT, these same factors amplify the clinical response.

Sleep Is Non-Negotiable

The majority of daily testosterone secretion occurs during sleep — specifically during slow-wave and REM stages. Studies show that restricting sleep to five hours per night drops daytime testosterone levels by up to 15%. For a hormone that's already declining 1–2% annually, that's a meaningful additional hit. Seven to nine hours of quality sleep is not optional for hormonal health.

RegenLife's lifestyle medicine approach addresses sleep architecture directly — not just sleep duration, but sleep quality, circadian alignment, and the nervous system regulation that determines how restorative sleep actually is. As explored in our guide to nervous system health, cortisol — the body's primary stress hormone — is a physiological antagonist to testosterone. Chronic stress, unmanaged, consistently lowers T regardless of what's being done in the gym.

Exercise and Body Composition

Resistance training is among the most reliably testosterone-supportive activities a person can do. Compound movements — squats, deadlifts, presses — acutely elevate testosterone and chronically improve hormonal signaling over time. HIIT also shows benefit. The caveat is recovery: chronic overtraining without adequate rest suppresses testosterone rather than raising it.

Body composition matters at least as much as training intensity. Excess visceral adipose tissue increases aromatase activity — the enzyme that converts testosterone to estrogen. Reducing body fat to a healthy range consistently raises testosterone levels. This is one of the many ways metabolic health and hormonal health are inseparable.

Nutrition and Key Micronutrients

Three micronutrients deserve particular attention:

• Zinc — directly involved in testosterone synthesis; correcting zinc deficiency reliably raises both total and free testosterone. Found in oysters, red meat, and pumpkin seeds.
• Vitamin D — functions as a steroid hormone precursor; supplementing in deficient men improves testosterone levels. Target 25-OH vitamin D ≥40 ng/mL.
• Magnesium — associated with higher free testosterone, particularly in physically active men. Found in leafy greens, nuts, and seeds.

Dietary fat also matters: testosterone synthesis requires cholesterol as a precursor. Very low-fat diets have been associated with lower T. This doesn't mean high-fat diets are therapeutic — it means the body needs adequate healthy fat (avocados, olive oil, whole eggs, nuts) to support steroid hormone production.

RegenLife's diagnostic services include micronutrient panels and metabolic testing, allowing clinicians to identify nutritional gaps that may be contributing to hormonal symptoms before or alongside TRT.